MarketCapExport financials
Burning Rock Biotech Limited (BNR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Burning Rock Biotech Limited Income Statement 2025-2011 | BNR
Brief overview of income trends at Burning Rock Biotech Limited
The figures are compared over a five-year interval. Revenue at Burning Rock Biotech Limited moved from 430 million yuan in 2020 to 540 million yuan in 2025. The cumulative result was +25.5%, corresponding to roughly 4.6% per year. The scale of the core business was largely unchanged.
Gross profit changed from 314 million yuan to 403 million yuan (+28.3%). Direct costs grew more slowly than revenue and improved the economics of sales. Comparing the endpoints gives gross margins of 73% and 74.7%. There was no meaningful shift in gross profitability.
Over the period, EBITDA shifted from −379 million yuan to −33.1 million yuan, a change of +91.3%. EBITDA expanded faster than the top line. At the operating-margin level, the figure shifted from −88.2% to −6.1%. The business generated more EBITDA from each unit of revenue.
The final result was −407 million yuan initially and −55.3 million yuan in the final year. The loss narrowed, although sustainable profitability has not yet returned.
Financial takeaway
Positive developments coexist with areas of weakness. The positive side is supported by a stronger final result, an improving EBITDA margin and better sales economics. The most visible risks are limited revenue growth and limited operating profitability. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Burning Rock Biotech Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | - | - | - | - | 2.95 B | - | - | - | - | - | - | - | - | - |
Shares |
- | - | - | - | - | 82.1 M | 23.5 M | 22.4 M | - | - | - | - | - | - | - |
Historical Prices |
3.11 | 7.49 | 25.8 | 23.6 | 8.43 | 36 | - | - | - | - | - | - | - | - | - |
Net Income |
-55.3 M | -347 M | -654 M | -971 M | -797 M | -407 M | -169 M | -177 M | -131 M | - | - | - | - | - | - |
Revenue |
540 M | 516 M | 537 M | 563 M | 508 M | 430 M | 382 M | 209 M | 111 M | - | - | - | - | - | - |
Cost of Revenue |
137 M | 153 M | 174 M | 183 M | 144 M | 116 M | 108 M | 73.8 M | - | - | - | - | - | - | - |
Gross Profit |
403 M | 362 M | 363 M | 380 M | 364 M | 314 M | 273 M | 135 M | 71.7 M | - | - | - | - | - | - |
Operating Income |
-54.8 M | -358 M | -669 M | -980 M | -797 M | -412 M | -169 M | -161 M | - | - | - | - | - | - | - |
Interest Expense |
-30 K | - | - | 102 K | 1.54 M | 667 K | 8.99 M | 18 M | - | - | - | - | - | - | - |
EBITDA |
-33.1 M | -305 M | -536 M | -856 M | -749 M | -379 M | -138 M | -137 M | -99.6 M | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | 726 M | 442 M | 296 M | 193 M | - | - | - | - | - | - |
General and Administrative Expenses |
126 M | 262 M | 438 M | 568 M | 490 M | 294 M | 132 M | 88.3 M | 76 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in CNY currency
Quarterly Income Statement Burning Rock Biotech Limited
| 2025-Q4 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.5 M | - | - | - | 22.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-55.3 M | -347 M | -654 M | - | - | - | - | -797 M | - | - | - | -407 M | - | - | - | -169 M | - | - | - | -177 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
540 M | 516 M | 537 M | - | - | - | - | 508 M | - | - | - | 430 M | - | - | - | 382 M | - | - | - | 209 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
137 M | 153 M | 174 M | - | - | - | - | 144 M | - | - | - | 116 M | - | - | - | 108 M | - | - | - | 73.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
403 M | 362 M | 363 M | - | - | - | - | 364 M | - | - | - | 314 M | - | - | - | 273 M | - | - | - | 135 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-54.8 M | -358 M | -669 M | - | - | - | - | -797 M | - | - | - | -412 M | - | - | - | -169 M | - | - | - | -161 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-30 K | - | - | - | - | - | - | 1.54 M | - | - | - | 667 K | - | - | - | 8.99 M | - | - | - | 18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-33.1 M | -305 M | -536 M | - | - | - | - | -749 M | - | - | - | -379 M | - | - | - | -138 M | - | - | - | -137 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
126 M | 262 M | 438 M | - | - | - | - | 490 M | - | - | - | 294 M | - | - | - | 132 M | - | - | - | 88.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in CNY currency
The income statement is one of the three key financial reports of a company Burning Rock Biotech Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Waters Corporation
WAT
|
$ 476.29 | -0.09 % | $ 28.4 B | USA |
 |
Exagen
XGN
|
$ 5.26 | -25.92 % | $ 113 M | USA |
 |
Celcuity
CELC
|
$ 67.13 | -4.11 % | $ 3.14 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 370.89 | -0.25 % | $ 30.9 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 101.65 | 0.63 % | $ 6.86 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
$ 664.97 | -1.18 % | $ 19.2 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 346.21 | -2.02 % | $ 17.2 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 750.2 | -0.69 % | $ 36.1 B |  Schweiz |
 |
Danaher Corporation
DHR
|
$ 236.19 | 0.46 % | $ 168 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 30.39 | -1.32 % | $ 28.8 B |  Niderland |
 |
RadNet
RDNT
|
$ 77.91 | -0.6 % | $ 5.86 B | USA |
 |
Senseonics Holdings
SENS
|
$ 10.05 | 2.55 % | $ 419 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | -7.8 % | $ 133 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 719.09 | -0.35 % | $ 271 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
$ 155.43 | -2.12 % | $ 19.5 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
$ 10.63 | -8.68 % | $ 361 M |  Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.19 | -6.2 % | $ 23.9 M |  Singapore |
 |
Natera
NTRA
|
$ 311.81 | -1.92 % | $ 42.6 B | USA |
 |
IQVIA Holdings
IQV
|
$ 275.46 | -1.21 % | $ 47.4 B | USA |
 |
Agilent Technologies
A
|
$ 178.84 | -0.74 % | $ 50.8 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
DexCom
DXCM
|
$ 79.92 | -1.42 % | $ 31.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 258.38 | -0.5 % | $ 28.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 34.41 | 0.07 % | $ 997 M | USA |
 |
IDEXX Laboratories
IDXX
|
$ 696.77 | -1.4 % | $ 56 B | USA |
 |
Illumina
ILMN
|
$ 214.84 | -2.69 % | $ 33.3 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.05 | -3.48 % | $ 99 K | USA |
|
Biodesix
BDSX
|
$ 10.04 | -2.95 % | $ 75.8 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.25 | 7.66 % | $ 6.81 M | USA |
 |
Bioventus
BVS
|
$ 11.18 | 1.5 % | $ 745 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 25.83 | -1.22 % | $ 795 M | USA |
 |
CareDx, Inc
CDNA
|
$ 80.78 | -4.31 % | $ 4.3 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Britain |
 |
Biomerica
BMRA
|
$ 1.48 | -4.52 % | $ 4.31 M | USA |